Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enalapril + spironolactone + carvedilol
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
enalapril + spironolactone + carvedilol is a combination pharmacological regimen investigated for the treatment of chronic Chagas cardiomyopathy. The regimen consists of two renin-angiotensin system (RAS) inhibitors—enalapril (an ACE inhibitor) and spironolactone (a mineralocorticoid receptor antagonist)—and carvedilol, a non-selective beta-blocker with alpha-1 blocking activity. This therapeutic strategy, studied by the Federal University of Minas Gerais in the NCT01557140 trial, aims to mitigate the progressive cardiac damage and neurohormonal activation characteristic of Trypanosoma cruzi infection. Clinical findings suggest the combination is safe and effective in improving left ventricular ejection fraction and clinical status in patients with Chagas-related heart failure.
- Other names
- RASi + carvedilolRAS inhibitors + carvedilol
02
Targets
PR (Progesterone receptor)ADRB1 (β1)ACE (Angiotensin Converting Enzyme)ADRB2 (β2)ADRA1A (α1A)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on enalapril + spironolactone + carvedilol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enalapril + spironolactone + carvedilol.